2004 - Fellow of the Royal Society of Edinburgh
Selective inhibition of BET bromodomains.
Panagis Filippakopoulos;Jun Qi;Sarah Picaud;Yao Shen.
p300/CBP proteins: HATs for transcriptional bridges and scaffolds
Ho Man Chan;Nicholas B. La Thangue.
Journal of Cell Science (2001)
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Omar Khan;Nicholas B La Thangue.
Immunology and Cell Biology (2012)
Chk2 activates E2F-1 in response to DNA damage
Craig Stevens;Linda Smith;Nicholas B. La Thangue.
Nature Cell Biology (2003)
Arginine methylation regulates the p53 response
Martin Jansson;Stephen T. Durant;Er Chieh Cho;Sharon Sheahan.
Nature Cell Biology (2008)
Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101
Jane A Plumb;Paul W Finn;Robert J Williams;Morwenna J Bandara.
Molecular Cancer Therapeutics (2003)
DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control.
Nicholas B. La Thangue.
Trends in Biochemical Sciences (1994)
HDAC inhibitor-based therapies: Can we interpret the code?
Maria New;Heidi Olzscha;Nicholas B. La Thangue.
Molecular Oncology (2012)
SETD2-Dependent Histone H3K36 Trimethylation Is Required for Homologous Recombination Repair and Genome Stability
Sophia X. Pfister;Sara Ahrabi;Lykourgos-Panagiotis Zalmas;Sovan Sarkar.
Cell Reports (2014)
Predictive biomarkers: a paradigm shift towards personalized cancer medicine.
Nicholas B. La Thangue;David J. Kerr.
Nature Reviews Clinical Oncology (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: